Mohawk Restasis deal could backfire on all pharma patent holders, not just Allergan
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Life sciences reporter
@IAM_Alerts RT @AMorrisReports: Read my interview with Judge Albright from earlier this week where he talks about the circuit's message about his handl… Read more
@IAM_Alerts The Long Read: Everything you wanted to know about patent rescue in Europe, but were too afraid to ask… https://t.co/i5R9TxId00 Read more
@IAM_Alerts While the global licensing deal agreed between InterDigital and Xiaomi yesterday was between two companies, it is i… https://t.co/lb7JUxOxSr Read more
@IAM_Alerts Alan Albright’s WDTX Waco court is the US’s busiest patent litigation venue - and the most controversial. In an exc… https://t.co/1PodkDA2Ny Read more